Artwork

Player FM - Internet Radio Done Right
Checked 11d ago
जोड़े गए twenty-two हफ्तों पहले
BioTalk Unzipped द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री BioTalk Unzipped या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal
Player FM - पॉडकास्ट ऐप
Player FM ऐप के साथ ऑफ़लाइन जाएं!
icon Daily Deals

Breakthrough in Melanoma, Rare Diseases, and Curative Therapies with Scott Schliebner

36:43
 
साझा करें
 

Manage episode 434915808 series 3593861
BioTalk Unzipped द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री BioTalk Unzipped या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal

Summary

In this episode, Scott Schliebner discusses the unique challenges and complexities of rare disease trials. He highlights the difficulties in recruiting patients, the multidisciplinary nature of care, and the importance of collaboration among various stakeholders. The role of AI in rare disease trials is also explored, with a focus on its potential for patient recruitment and data analysis.

Scott shares success stories in the field and discusses the expanding use of gene therapy to target multiple genes. The conversation concludes with a discussion on the recent FDA approval of Iovance's Amtogvy as the first T-cell therapy for a solid tumor, Melanoma. In this conversation, Scott discusses the potential of cell therapy in targeting solid tumors, particularly melanoma. He highlights the importance of expanding the use of cell therapy to other tumor types and the potential for curative treatments. The conversation also delves into the challenges and questions surrounding pricing and ethics in the gene and cell therapy space. The impact of curative therapies on quality of life and healthcare costs is explored, along with the success of curative therapies in hepatitis C. The high bar of clinical development and regulatory standards is discussed, as well as the potential for cost-effective treatments. The conversation concludes with advice for young professionals and established clinical professionals in the field of drug development.

Takeaways

  • Cell therapy shows promise in targeting solid tumors, such as the breakthrough in melanoma treatment, and has the potential to provide curative treatments for various cancer types.

  • The pricing and ethical considerations surrounding gene and cell therapy raise important questions about accessibility and affordability.

  • Curative therapies have the potential to significantly improve quality of life and reduce healthcare costs by eliminating the need for long-term treatments.

  • The success of curative therapies in hepatitis C demonstrates the potential for similar breakthroughs in other disease areas.

  • Young professionals interested in a career in clinical drug development should seek opportunities to gain experience and consider starting in roles such as clinical research coordinators or clinical research associates.

  • Rare Givers is a nonprofit organization that supports caregivers in the rare disease space.

Chapters

00:21 - Collaborative Approach in Rare Disease Trials

3:32 - The Role of AI in Rare Disease Trials

6:11 - Success Stories in Rare Disease Trials

11:34 - Expanding Gene Therapy to Target Multiple Genes

16:56 - New News: FDA Approval of Iovance's Amtagvi, The Breakthrough of IOVANCE for Melanoma

19:27 - Targeting Solid Tumors with Cell Therapy, Expanding the Potential of Cell Therapy

20:23 - The Impact of Curative Therapies on Quality of Life and Healthcare Costs

21:11 - Challenges and Questions around Pricing and Ethics

22:37 - Cures for Hepatitis C

23:25 - The High Bar of Clinical Development and Regulatory Standards

24:05 - Pricing Considerations for Different Cancer Types, The Potential for Cost-Effective Treatments

27:45 - Advice for Young Professionals in Clinical Drug Development

31:49 - Advice for Established Clinical Professionals

33:21 - Scott's Hobbies and Interests

Learn about and DONATE to Rare Givers:

https://www.raregivers.global/

How to reach us:

Scott Schliebner

https://www.linkedin.com/in/scott-schliebner-1087789/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

New News Link:

https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor

Image Credits

Iovance, https://www.iovance.com/

FDA approved, https://www.tipranks.com/news/iovance-nasdaqiova-fda-approves-cell-therapy-stock-gains

Amtagvi, https://www.amtagvi.com/

  continue reading

29 एपिसोडस

Artwork
iconसाझा करें
 
Manage episode 434915808 series 3593861
BioTalk Unzipped द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री BioTalk Unzipped या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal

Summary

In this episode, Scott Schliebner discusses the unique challenges and complexities of rare disease trials. He highlights the difficulties in recruiting patients, the multidisciplinary nature of care, and the importance of collaboration among various stakeholders. The role of AI in rare disease trials is also explored, with a focus on its potential for patient recruitment and data analysis.

Scott shares success stories in the field and discusses the expanding use of gene therapy to target multiple genes. The conversation concludes with a discussion on the recent FDA approval of Iovance's Amtogvy as the first T-cell therapy for a solid tumor, Melanoma. In this conversation, Scott discusses the potential of cell therapy in targeting solid tumors, particularly melanoma. He highlights the importance of expanding the use of cell therapy to other tumor types and the potential for curative treatments. The conversation also delves into the challenges and questions surrounding pricing and ethics in the gene and cell therapy space. The impact of curative therapies on quality of life and healthcare costs is explored, along with the success of curative therapies in hepatitis C. The high bar of clinical development and regulatory standards is discussed, as well as the potential for cost-effective treatments. The conversation concludes with advice for young professionals and established clinical professionals in the field of drug development.

Takeaways

  • Cell therapy shows promise in targeting solid tumors, such as the breakthrough in melanoma treatment, and has the potential to provide curative treatments for various cancer types.

  • The pricing and ethical considerations surrounding gene and cell therapy raise important questions about accessibility and affordability.

  • Curative therapies have the potential to significantly improve quality of life and reduce healthcare costs by eliminating the need for long-term treatments.

  • The success of curative therapies in hepatitis C demonstrates the potential for similar breakthroughs in other disease areas.

  • Young professionals interested in a career in clinical drug development should seek opportunities to gain experience and consider starting in roles such as clinical research coordinators or clinical research associates.

  • Rare Givers is a nonprofit organization that supports caregivers in the rare disease space.

Chapters

00:21 - Collaborative Approach in Rare Disease Trials

3:32 - The Role of AI in Rare Disease Trials

6:11 - Success Stories in Rare Disease Trials

11:34 - Expanding Gene Therapy to Target Multiple Genes

16:56 - New News: FDA Approval of Iovance's Amtagvi, The Breakthrough of IOVANCE for Melanoma

19:27 - Targeting Solid Tumors with Cell Therapy, Expanding the Potential of Cell Therapy

20:23 - The Impact of Curative Therapies on Quality of Life and Healthcare Costs

21:11 - Challenges and Questions around Pricing and Ethics

22:37 - Cures for Hepatitis C

23:25 - The High Bar of Clinical Development and Regulatory Standards

24:05 - Pricing Considerations for Different Cancer Types, The Potential for Cost-Effective Treatments

27:45 - Advice for Young Professionals in Clinical Drug Development

31:49 - Advice for Established Clinical Professionals

33:21 - Scott's Hobbies and Interests

Learn about and DONATE to Rare Givers:

https://www.raregivers.global/

How to reach us:

Scott Schliebner

https://www.linkedin.com/in/scott-schliebner-1087789/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

New News Link:

https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor

Image Credits

Iovance, https://www.iovance.com/

FDA approved, https://www.tipranks.com/news/iovance-nasdaqiova-fda-approves-cell-therapy-stock-gains

Amtagvi, https://www.amtagvi.com/

  continue reading

29 एपिसोडस

सभी एपिसोड

×
 
In this episode of BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe welcome Dr. Nathan Teuscher, a seasoned expert in clinical pharmacology and pharmacometrics. The conversation explores Nathan's career journey, the innovative charity Light the World, and the transformative role of AI in drug development. They discuss the challenges and opportunities presented by AI, particularly in automating data analysis and rethinking traditional reporting methods in the pharmaceutical industry. The episode emphasizes the potential for small companies to leverage cloud-based tools and APIs to enhance efficiency and drive innovation in drug development. In this conversation, the speakers explore the intersection of data analysis, AI tools, and advancements in gene editing with organ transplants. Chapters 00:00 Episode Preview 00:55 Introduction to BioTalk Unzipped 02:06 Charity Spotlight: Light of the World 04:51 Nathan Teuscher's Career Journey 07:34 Differentiating AI Types in Life Science 12:41 Challenges with Large Language Models 15:39 Rethinking Reporting in Pharma 17:56 The Future of AI and Analytics in Pharma? 18:52 Leveraging APIs (Application Programming Interfaces) for Small Companies 23:05 Leveraging Data, AI, and APIs in 3 Dimensions 26:22 NEW NEWS! - Gene Editing Breakthroughs in Medicine How to reach us: Light the World Charity - Church of Jesus Christ Latter Day Saints https://www.churchofjesuschrist.org/comeuntochrist/light-the-world Nathan Teuscher https://www.linkedin.com/in/nathanteuscher/ Aplos Analytics - https://aplosanalytics.com/ Nathan Teuscher’s Podcast: Clinical Pharmacology Podcast https://teuschersolutions.com/ Collaboration with BioTalk Unzipped (Ep. 40) https://podcasts.apple.com/us/podcast/collaboration-with-biotalk-unzipped-ep-40/id1695617234?i=1000682122951 Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Sound Bites "We don't need to write reports anymore." Takeaways Nathan Teuscher has over 20 years of experience in clinical pharmacology and pharmacometrics. Light the World charity offers unique giving machines for donations. AI can automate repetitive tasks in drug development, freeing up human capital for innovation. There are two types of AI: large language models and automated data analysis. Large language models can be unreliable in scientific contexts. Pharmaceutical companies spend significant resources on report writing, which may not add value. Small companies can leverage APIs to access standardized calculations and data analysis. The pharmaceutical industry is often insular, limiting the potential of AI. AI could potentially eliminate the need for extensive written reports in drug development. Collaboration and data sharing are crucial for advancing AI in the pharmaceutical industry. Leveraging data effectively requires combining various data sets and tools. The evolution of AI tools is crucial for navigating new technologies. Gene editing represents a significant breakthrough in organ transplantation. New News Story: A woman in the US is the third person to receive a gene-edited pig kidney https://www.technologyreview.com/2024/12/17/1108905/a-woman-in-the-us-is-the-third-person-to-receive-a-gene-edited-pig-kidney/ Image Credits Pig Kidney, https://ny1.com/nyc/all-boroughs/news/2023/08/16/pig-kidney-works-in-a-donated-body-for-over-a-month--a-step-toward-animal-human-transplants Keywords BioTalk, pharmacology, AI in pharma, drug development, pharmacometrics, software development, clinical research, Light the World, charity, data analysis, AI tools, gene editing, kidney transplant, pharmaceuticals, virtual trials, healthcare innovation, drug development, patient engagement, medical technology, drug dosage, oncology, FDA approval, cell therapy, immunocompromised, collaboration, success, clinical pharmacology, podcast, healthcare…
 
In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients. Chapters 00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360 03:45 Samaritan's Purse Charity and Community Impact 05:16 Most impactful talk at AAPS? 11:50 Comparative Analysis of FDA and EU Regulations 17:37 The Drive Behind Bioanalytical Work 22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis Takeaways ​The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials. ​Community support through charities like Samaritan's Purse is crucial during crises. ​The importance of collaboration in advancing drug development and bioanalytical methods. ​Innovations in RNA editing present new bioanalytical challenges. ​The drive to help patients is a key motivator for professionals in the field. ​ Sound Bites ​"I worked on that drug and there's a clear benefit." ​"It's getting that new therapy to a patient." ​"This is going to change and potentially delay biomarkers." ​ New News Story: ​Wave sees RNA editing validation in early trial results ◦ https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/ How to reach us: Please donate to: Samaritan’s Purse https://www.samaritanspurse.org/ Mark Arnold https://www.linkedin.com/in/markearnoldphd/ Blog - https://bioanalysisandbiomarkers.blogspot.com/ Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Image Credits ​AAPS…
 
BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe engage with Dr. Tomas Helikar in an exciting discussion on the future of AI, digital twins, and personalized medicine. From mathematical models and immune system simulations to groundbreaking collaborations with the Department of Defense, this episode uncovers how digital twins have the potential to transform drug discovery and clinical trials. Don’t miss insights on the ethical challenges of data privacy, the promise of animal digital twins, and the latest AI breakthroughs like MIT’s Sparrow algorithm! Chapters 01:00 How the mathematical models work. Normalization and Scaling in Computational Biology 07:55 Focus on the Immune System and Organ Models 09:05 Collaboration with the Department of Defense 11:03 Drug Discovery and Digital Twins 13:43 NEW NEWS! - AI in Drug Discovery: The MIT Sparrow Algorithm 17:51 Future of Digital Twins in Clinical Trials 18:59 Personalized Medicine and Individualized Treatments 23:33 The Potential of Animal Digital Twins 24:59 Building a Research Infrastructure for Digital Twins 26:03 Privacy and Ownership of Digital Twin Data 30:14 Encouraging Publication and Literature Engagement How to reach us: Tomas Helikar https://www.linkedin.com/in/tomashelikar/ X - https://x.com/tomashelikar Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Sound Bites "Publications are the currency in academia." New News Story: MIT’s SPARROW Redefines Drug Discovery With Smart Synthesis https://scitechdaily.com/mits-sparrow-redefines-drug-discovery-with-smart-synthesis/ Image Credits MIT Molecule, https://news.mit.edu/topic/algorithms?page=2…
 
Dr. Tomas Helikar, a leading researcher in bioinformatics and systems biology, delves into groundbreaking work on developing a personalized immune digital twin, which aims to revolutionize the understanding and treatment of immune-related diseases. Chapters 00:00 Introduction to BioTalk Unzipped 01:50 Meet Dr. Tomas Helikar 04:34 The Journey into Systems Biology 10:03 Understanding Digital Twins in Immunology 14:19 The Importance of Personalized Medicine 17:20 Digital Twin Research Funding and Its Impact 18:38 The Role of Digital Twins in Disease Management 21:11 Digital Twin Efforts for Organ Transplants 24:05 Computational Challenges in Modeling 26:36 Mathematical Models in Biological Research 28:11 - NEW NEWS! - Twist Joins Absci in AI Antibody Collaboration How to reach us: Tomas Helikar https://www.linkedin.com/in/tomashelikar/ X - https://x.com/tomashelikar Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Charity Mentioned: https://saintpeterlincoln.com/school FOLLOW ► LinkedIn: https://www.linkedin.com/company/biotalk-unzipped Twitter: https://x.com/BiotalkUnzipped Instagram: https://www.instagram.com/biotalkunzipped/ Takeaways Dr. Helikar's research focuses on the immune system's network and disease. Systems biology integrates computer science and biology for better understanding. Digital twins can provide personalized models for immune system analysis. Your digital twin model could tell you how you might respond to a particular disease and if you really need to go to the hospital. The immune digital twin reflects an individual's unique immune baseline. Research funding is crucial for advancing innovative medical technologies. Personalized medicine can improve public health outcomes significantly. Computational power is essential for processing complex biological data. Mathematical models are vital for simulating biological processes. Digital twins can enhance drug discovery and clinical trial efficiency. Sound Bites "The immune system is a network of networks." “Each of our immune system baselines are different.” "We need to build out this multi-scale model." New News Story: Supplier-Turned-Partner: Twist Joins Absci in AI Antibody Collaboration https://www.genengnews.com/topics/drug-discovery/supplier-turned-partner-twist-joins-absci-in-ai-antibody-collaboration/ Image Credits Signal Transduction, www.scientificanimations.com - http://www.scientificanimations.com/wiki-images/ Computational Model, https://computationstructures.org/notes/models/notes.html Holland computer center, https://newsroom.unl.edu/announce/cse/16380/90600 https://news.unl.edu/article/husker-football-game-day-information-announced-for-2023 https://hcc.unl.edu/office-locations…
 
Dr. Mark Arnold, a distinguished bioanalytical thought leader with an impressive track record in supporting drug development programs. Mark is the Owner and Principal at Bioanalytical Solution Integration, where he provides strategic counsel on complex bioanalytical assays and regulatory compliance. With over 35 years of experience, including leadership roles at BMS and Labcorp, Mark has become a key figure in the biotech and pharma industries. He is also an AAPS Fellow and a founder of the Global Bioanalysis Consortium. 01:05 - Career Reflections and Contributions to Drug Development 05:28 - Understanding the Integration of Drug Development 09:30 - What Would You Change? Embracing Career Risks in Pharma 11:32 - Navigating Career Paths: Small vs. Large Companies 16:09 - NEW NEWS! - Can Electrical Fields Disrupt Cancer? 23:28 - The Role of AI in Drug Development 31:13 - Encouraging Innovation in a Regulated Industry Follow Mark, Chad and Gregory: Please donate to: Samaritan’s Purse https://www.samaritanspurse.org/ Mark Arnold - https://www.linkedin.com/in/markearnoldphd/ Blog - https://bioanalysisandbiomarkers.blogspot.com/ Dr. Chad Briscoe - https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin - https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / BioTalk Unzipped on LinkedIn - https://www.linkedin.com/company/biotalk-unzipped/ New News Story: Novocure wins FDA approval for electric field device in lung cancer https://www.biopharmadive.com/news/novocure-fda-lung-cancer-approval-optune-lua-tumor-treating-field/729997 Two articles on finding 1000’s of dark matter RNA viruses: https://www.fiercebiotech.com/research/deep-learning-ai-model-scans-dark-matter-genomic-data-and-finds-70000-never-seen-rna https://www.nature.com/articles/d41586-024-03320-6 Image Credits Novocure images courtesy of Novocure: www.novocure.com…
 
EP-23. In the second half of this compelling conversation on BioTalk Unzipped , Gregory Austin and Dr. Chad Briscoe continue their deep dive with Scott Ogle, CEO of TruLab. They explore the surprising parallels between the banking and pharma industries, the game-changing role of digital twinning in clinical trials, and the biotech funding landscape. Scott also shares his thoughts on leadership, mentorship, and the impact of the Inflation Reduction Act on pharma innovation. This episode offers listeners valuable insights into the future of drug development and the challenges of balancing professional and personal life in a fast-paced industry. Chapters 1:09 - Comparison of the Banking Industry to the Pharma Industry 5:18 - Data Integrity, Same For Decentralized Trials? 8:33 - Biotech Funding Trends 11:18 - NEW NEWS! – Digital Twinning in Clinical Trials 16:15 - What Advice Would You Give to Your Younger Self? 20:57 - Mentorship and Its Impact, How it Shaped Scott 23:45 - Balancing Work and Personal Life 24:32 - The Inflation Reduction Act and Innovation Takeaways The regulatory environment in pharma can slow down innovation. Digital twinning in clinical trials could revolutionize drug development. Family influences play a significant role in shaping business perspectives. The need for a strong company culture to maintain values during growth. Biotech funding trends are influenced by macroeconomic factors like interest rates. The importance of mentorship in professional development. Sound Bites “The similarities between the banking industry and the pharma industry is eerily similar.” “Quality is really what we do.” “Being quality is core to software.” “It’s really clear people care more about their money than they do their healthcare.” “Biotech and large pharma seem to balance each other out.” “The career for you is at the intersection of what you are good at and what you like to do.” “If you’re good at something and you like to do it, it fuels your energy to keep getting better.” “Enjoy the impact in what you’re doing and accomplishing!” New News Story: Digital “Twinning”: Clinical Trials Powered by AI https://www.sanofi.com/en/magazine/our-science/digital-twinning-clinical-trials-ai How to reach us: Scott Ogle https://www.linkedin.com/in/scott-ogle/ TruLab - https://trulab.com/ Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Image Credits Digital Twinning - Credit Getty Images Simulation - Credit: andrush / Adobe Stock Tomáš Helikar - https://www.linkedin.com/in/tomashelikar/ Nebraska Swan computer - https://newsroom.unl.edu/announce/cse/16380/90600 Brian Hamilton - https://inmatestoentrepreneurs.org/board/brian-hamilton/…
 
Summary In this 22nd episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Scott Ogle, CEO of TrueLab, discussing his journey from finance to the pharmaceutical industry, the impact of personal experiences on innovation, and the importance of technology in clinical trials. They explore how to hire the best employees in this climate, the significance of company culture, and the influence of family on business perspectives. Chapters 00:00 Introduction to BioTalk Unzipped 03:15 The Impact of Personal Experience on Innovation 08:47 TruLab's Technology and Its Role in Clinical Trials 14:33 The Importance of Sample Management and the Genesis of TruLab 20:33 NEW NEWS! – The Future of Cancer Treatments 23:34 Hiring Patterns and the value of Company Culture Takeaways Scott Ogle's personal experience with his father's illness inspired the creation of TruLab. TruLab focuses on eliminating inefficiencies in clinical trial sample management. The importance of having fun in one's career for productivity and happiness. Hiring for energy and cultural fit is crucial for company success. More young people out of college actually prefer working in the office, so it’s a hiring advantage. Sound Bites “Entrepreneurs get excited about their solution but can forget about what problem they’re solving.” "We need to iterate on technology in clinical trials." “20-25% of biological samples get tossed out.” "You can't coach energy in a candidate." “Company values. Senior leadership must beat it like a drum.” “Interviewing candidates on company values is your North Star.” “Go by what people do, not by what they say.” “Hallway meetings, that’s where stuff gets done.” New News Story: ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells https://www.nature.com/articles/s43018-024-00821-1 How to reach us: Scott Ogle https://www.linkedin.com/in/scott-ogle/ TruLab - https://trulab.com/ Leukemia & Lymphoma Society - https://www.lls.org/ Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Keywords: Scott Ogle, TruLab, clinical trial technology, biotech innovation, sample management in clinical trials, hiring for company culture, company values in leadership, finance to pharma journey, revolutionizing clinical trials, impact of personal experience on innovation, biotechnology leadership, clinical trial inefficiencies, cancer treatment news, digital transformation in pharma, family influence in business, company culture in biotech, pharmaceutical funding challenges, ISB 2001 trispecific T cell engager. Tags: #ScottOgle, #TruLab, #ClinicalTrials, #Biotech, #PharmaInnovation, #Sample Management, #Company Culture, #Hiring Tips, #BiotechLeadership, #PharmaTechnology, #CancerTreatment, #PersonalInnovation, #BiotechFunding, #LeadershipInPharma, #BusinessLeadership, #PharmaceuticalIndustry.…
 
Mentoring in Pharmaceutical Science with Dr. Jim Shen Summary In Episode 21 of BioTalk Unzipped, host Gregory Austin and co-host Dr. Chad Briscoe interview Dr. Jim Shen, the executive director and head of regulated bioanalysis operations at BMS. Jim discusses his early career in bioanalysis and the importance of mentorship. He emphasizes the need to recognize and appreciate the success and expertise of others, as well as the importance of building a network of champions, allies, and sponsors. The conversation also touches on the topic of psychedelics as a drug therapy and the recent retraction of scientific papers on MDMA-assisted therapy. Jim shares his passion for photography, particularly infrared photography, and the resurgence of film photography. Chapters 01:14 - Jim’s Favorite Publication and His Journey into Bioanalysis 04:15 - Finding Joy in Your Work: Pursuing Your Interests and Making a Difference 05:10 - Early Career in Bioanalysis 07:35 - The Importance of Mentorship and Dealing With Adversaries 17:35 - NEW NEWS: Retraction of Scientific Papers on Drug Therapy 24:55 - Personal Interests: Photography and Gaming Takeaways Dr. Shen's journey into bioanalysis highlights the importance of pursuing your interests and finding enjoyment in your work, even if it may not align with your initial plans. Building a supportive and collaborative community is crucial in the field of bioanalysis, where knowledge sharing and networking play a significant role in advancing research and innovation. Recognize and appreciate the success and expertise of others Build a network of champions, allies, and sponsors Be open to new career opportunities and emerging fields Maintain integrity and transparency in scientific research Explore different hobbies and interests outside of work Sound Bites “Sponsors are those with the power to change your career. Those people don't come along very often, so you need to really grab them when you see them.” “EQ is so important in being successful in your larger pharmaceutical company.” “I first tell my staff to divide people into 3 groups, champions, allies, and sponsors.” “And it is very hard to be in this field, to be a scientist, but you know, it's the people that make it worthwhile.” New News Story: Following FDA rejection, a journal retracts papers on MDMA-assisted therapy https://www.biopharmadive.com/news/lykos-journal-mdma-retractions-maps-ptsd-unethical-conduct/723945/ How to reach us: Dr. Jim Shen https://www.linkedin.com/in/jimxshen/ Bristol Myers Squibb - https://www.bms.com/ Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Image Credits Travis Kelce: https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DQY8xlVldVp8&psig=AOvVaw2yCKg3oh923dt0beIIR8w3&ust=1726284386832000&source=images&cd=vfe&opi=89978449&ved=0CBcQjhxqFwoTCICN_OD8vogDFQAAAAAdAAAAABB2 https://www.te-university.com/posts https://people.com/travis-kelce-says-hes-his-own-worst-critic-on-the-field-8684839 https://www.marca.com/en/nfl/kansas-city-chiefs/2023/07/12/64aec11a268e3e242d8b458e.html https://www.newheightshow.com/ https://www.aol.com/fans-think-moment-travis-kelce-185629668.html World of Warcraft Guilds https://www.dexerto.com/world-of-warcraft/wow-players-critical-of-unrealistic-guild-expectations-for-season-of-discovery-2392361/ Infrared Photography: Jim Shen Keywords Pharmaceutical, Mentor, Mentorship, Mentoring, Science, Biotech, Biotechnology, Gaming, Photography, Bioanalysis…
 
In this episode (EP20) of BioTalk Unzipped, host Gregory Austin and co-host Dr. Chad Briscoe interview Dr. Jim Shen, the Executive Director and Head of Regulated Bioanalysis Operations at BMS. They discuss topics such as the advancements in cancer therapies, the integration of AI and mechanistic modeling in drug development, and the complexities of regulatory submissions. Dr. Shen shares his journey into bioanalysis and his passion for mass spectrometry. Chapters 01:15 - Introduction, Background, and Passion for The American Cancer Society 03:46 - Advancements in Cancer Therapies, Opdualag 08:03 - From Small Molecule to Large to Hybrid 12:52 - NEW NEWS! - Halda Raises $126M for a New Targeted Cancer Therapy 18:30 - Dr. Shen’s Journey from Computers to Chemistry into Bioanalysis 27:00 - The Integration of AI and Mechanistic Modeling in Drug Development 34:30 - Navigating the Complexities of Regulatory Submissions Takeaways Advancements in cancer therapies, such as immunotherapy and antibody drug conjugates, have revolutionized the treatment landscape and improved patient outcomes. The integration of AI and mechanistic modeling in drug development shows promise but is still in its infancy. More research and collaboration between software and hardware engineers are needed to fully realize its potential. Navigating the complexities of regulatory submissions requires adherence to international guidelines and validation of analytical methods to ensure accuracy and precision. Dr. Shen's journey into bioanalysis highlights the importance of pursuing your interests and finding enjoyment in your work, even if it may not align with your initial plans. Sound Bites "Advancements in cancer therapies have revolutionized the treatment landscape." "Antibody drug conjugates are one of the most exciting and interesting types of molecules." "The integration of AI and mechanistic modeling in drug development shows promise but is still in its infancy." New News Story: Startup Halda raises $126M to advance new type of targeted cancer therapy https://www.biopharmadive.com/news/halda-series-b-riptac-prostate-cancer/723933/ How to reach us: American Cancer Society https://www.cancer.org/ Dr. Jim Shen https://www.linkedin.com/in/jimxshen/ Bristol Myers Squibb - https://www.bms.com/ Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Images ADC Mechanism of Action https://www.researchgate.net/figure/Antibody-drug-conjugate-ADC-structure-and-mechanistic-schematic-Inset-in-upper-right_fig1_364183953 https://www.researchgate.net/figure/General-structure-of-antibody-drug-conjugate_fig1_355319441 Keywords Bioanalysis, Cancer, Oncology, Research, Drug Development, Compliance, Regulatory Compliance, AI, ADC, Antibody Drug Conjugates, immunotherapy, Pharmaceutical, Biotechnology, Podcast, Science, Pharmaceutical Science…
 
In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe continue their conversation with Zealic CEO, Chuck Piccirillo. They delve into the unique challenges of the patient journey and the increasing demand for hybrid healthcare solutions that offer more flexibility. The discussion highlights the rise of virtual health, particularly in Europe, and introduces exciting developments in ion channels as a goldmine for new medicines. They also explore the financial intricacies of drug development, the importance of leadership through incremental steps, the value of in-person interactions, and hard-earned lessons in the industry. Finally, Chuck offers invaluable advice for entrepreneurs in the life sciences sector. Chapters 00:17 - Adapting to what is unique in the patient journey. 07:08 - Push for hybrid solutions - more flexibility. 09:20 - Virtual health is emerging, especially in Europe. 14:02 - New News! - Ion Channels are a goldmine for new medicines 19:23 - The Financial Side of Drug Development 21:50 - Leadership - Incremental Steps, the Value of In-Person Interactions, Learning Hard Lessons 30:58 - Advice For Entrepreneurs in Life Science Takeaways Building blocks to build the digital patient experience, then tweak it to the individual drug and form a complex digital and personal adaptive health journey. The healthcare industry needs to find a balance between safety and innovation to ensure patients have access to the best possible care. Remote patient monitoring and decentralized clinical trials are crucial in improving patient engagement and outcomes in the healthcare industry. Virtual visits and technology integration can enhance patient engagement and make healthcare more accessible. While there has been an increase in decentralized trials, the focus is currently on commercial solutions due to the crowded nature of the clinical trial technology space. Virtual health and routine monitoring have the potential to alleviate the burden on healthcare providers and improve patient care. Ion channel research holds promise for developing new medicines and treatments for various conditions. Incremental progress and persistence are key in entrepreneurship and leadership. Sound Bites (regarding adaptability in clinical software) “Imagine if LinkedIn only every 6 months. How engaging would that be?” "And it would actually integrate with like Uber, for example, and help them get a ride if they had to go to the doctor and actually, and all of that is based on these building blocks that we're able to assemble and then press a button." “I think everybody wants whatever aspect of life nowadays to be hybrid anything.” “It’s why we always talk about pragmatic innovation.” “Persistence in the face of opposition of all sorts.” New News Story: These microscopic tunnels are a goldmine for new medicines https://www.biopharmadive.com/news/ion-channels-drug-research-vertex-biohaven-jazz/719337/ How to reach us: Crohn's & Colitis Foundation https://www.crohnscolitisfoundation.org/ Chuck Piccirillo https://www.linkedin.com/in/cpiccirillo/ Zealic Health - http://www.zealichealth.com Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Keywords Patient Journey, Hybrid Healthcare Solutions, Drug Development Finance, Leadership in Life Sciences, Entrepreneurship in Life Sciences, Remote Patient Monitoring, Decentralized Clinical Trials, Healthcare Technology Integration, Digital Patient Experience, Clinical Software Adaptability, Pragmatic Innovation, Persistence in Entrepreneurship, Leadership #HealthcareInnovation #VirtualHealth #DrugDevelopment #LifeSciences #Entrepreneurship #DigitalHealth #HybridHealthcare #IonChannels #PatientCare #RemoteMonitoring #ClinicalTrials #Leadership #HealthTech #PragmaticInnovation #Persistence #pharmaceutical #biotech #science #CEO…
 
Summary In this conversation, Dr. Jonathon Hill discusses the unique partnership between his lab and the university, which allows students to become entrepreneurs, develop their own projects, and become the CEO. Dr. Hill discusses the potential for AI to better diagnose disease based on the individual’s genome. He also talks about Lumicell's fluorescent system for highlighting residual breast cancer tissue and the importance of genetic diagnostics in personalized medicine. Dr. Hill shares his advice for students interested in genetics and biotechnology research, emphasizing the value of research experience and taking risks. He also discusses the challenges of regulatory pathways in the biotech industry. Takeaways The unique partnership between academic institutions and companies can provide students with opportunities to develop their own ideas and become entrepreneurs, fostering innovation and impact in the biotechnology industry. Lumicell's fluorescent system can help detect residual breast cancer tissue, reducing the need for additional surgeries Genetic diagnostics will play a crucial role in personalized medicine, but there are limitations to relying solely on genetic sequencing Navigating regulatory pathways is a challenge in the biotech industry Sound Bites “We like to say that we are creating CEOs in our labs … CEO at age 23.” “When you go to the doctor, they do a guess and check model.” “Why did you not carefully diagnose the problem and give me the right treatment the first time?” “And medicine needs to go in the direction of AI-aided diagnosis because it's going to lower costs, make things faster and more efficient and better in the long run if we can create if we can create accurate diagnoses.” “Typically about 50% of high school seniors indicate they will go to college. This year it’s down to 37%” Chapters 01:01-The balance between being professor and running a lab 02:00-The unique partnership between university and industry 03:55-More students are looking to pursue entrepreneurship out of college 06:31-How will AI affect genetics research and the industry? The impact of AI in future diagnoses. 12:58-New News! Lumcell’s breakthrough in residual breast cancer imaging detection. 16:10-Dr Hill’s passions within and outside his professional life. 17:37-Advice for young scientists and budding biotech entrepreneurs. 21:00-Growth of bioinnovations and training scientific students for business success vs. backlash of the cost of education. 28:48-The regulatory hurdles and progress for Wasatch and their DNA research. New News Article The FDA has granted a groundbreaking approval to a fluorescent light system that illuminates leftov... https://www.fiercebiotech.com/medtech/fda-delivers-approval-lumicells-fluorescent-system-highlighting-residual-breast-cancer How to reach us: Dr. Jonathon Hill https://www.linkedin.com/in/jonathon-t-hill/ Wasatch Labs: https://www.wasatchbiolabs.com/ Rainforest Trust - https://www.rainforesttrust.org/ Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Image Credits Gattaca https://www.justwatch.com/us/movie/gattaca Lumicell Fluorescent System https://www.fiercebiotech.com/medtech/fda-delivers-approval-lumicells-fluorescent-system-highlighting-residual-breast-cancer https://www.laserfocusworld.com/bio-life-sciences/article/14294960/fluorescence-imaging-system-may-improve-cancer-care https://vimeo.com/807609920 https://healthandpharma.net/fda-approves-imaging-tumor-detection-breast-cancer-surgeries#google_vignette Keywords nanopore sequencing, genetic research, epigenetics, rainforest preservation, AI, tobacco addiction, addiction treatment, Alzheimer's disease, DNA methylation #nanopore, #geneticresearch, #epigenetics, #AI, #addiction, #alzheimers, #DNA…
 
Summary In this conversation, Gregory Austin and Chad Briscoe interview Chuck Piccirillo, CEO of Zealic Health, about his experience in the healthcare industry and the focus on patient-centric solutions. Chuck shares his personal journey with colitis and how it ultimately inspired him to start Zealic Health. The company aims to provide highly patient-centric digital platforms to improve care and treatment in the healthcare industry. Chuck also shares the story of how Zealic Health adapted to the war in Ukraine and relocated their employees to Poland. The panel tackles the tough questions around the new LDT as a Medical Device final ruling by the FDA. They then discuss how AI is helping doctors detect cancer and in making better diagnostic decisions. Takeaways Zealic Health focuses on providing patient-centric digital platforms to improve care and treatment in the healthcare industry. The use of AI in healthcare can help accelerate drug development, improve diagnostics, and enhance patient engagement. Zealic Health adapted to the war in Ukraine by relocating their employees to Poland, demonstrating their commitment to their team and their mission. The FDA final ruling is clearly to improve safety but the confusion is in the interpretation of that ruling and Sound Bites “The biggest challenge is the interpretation of these (LDT) rules.” “Typically I’m not in favor of what Congress is doing.” “Trying to understand how we’re going to navigate the space … it’s just been confusing.” "The FDA is trying to protect us, but they need to navigate these things and engage industry experts." “(regarding AI) Where does marketing end and reality begin?” "AI isn't going to say, 'We don't need the doctor, just use AI.'" “The people who are out of their jobs won't be the ones using AI. The people who are out of their jobs will be the ones who don't.” “The whole promise of AI is taking massive amounts of data and finding those patterns Chapters 01:33 Introduction and Background 04:03 The Crohn’s & Colitis Foundation and Chuck’s struggle with Colitis 07:49 Patient-Centric Solutions in Healthcare and Zealic Health 13:26 Plan B - Moving offices from Ukraine to Poland 20:02 New News!! - The Controversy of LDTs Becoming Medical Devices 27:20 Implications of healthcare and regulations as it applies to AI 30:07 How AI Aids in Diagnosis New News Story: House committee tells FDA to suspend lab developed test rule https://www.healthcaredive.com/news/house-committee-fda-suspend-ldt-rule/721362/ How to reach us: Crohn's & Colitis Foundation https://www.crohnscolitisfoundation.org/ Chuck Piccirillo https://www.linkedin.com/in/cpiccirillo/ Zealic Health - http://www.zealichealth.com Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Image credits: https://www.crohnscolitisfoundation.org/ LDT/FDA, https://x.com/FDADeviceInfo/status/1784965525522493657 Congress, https://worldstrides.com/blog/2013/07/u-s-capitol/ Cost, https://www.freepik.com/photos/increasing-costs Cancer patient, https://www.freepik.com/free-photo/sick-asian-man-sitting-chair-side-view_33753979.htm CAD - Computer Aided Detection, https://researchoutreach.org/articles/assessing-performances-computer-aided-diagnosis-breast-cancer/ #BioTalkUnzipped #Podcast #HealthcareInnovation #PatientCare #AIinHealthcare #FDARegulations #Ukraine #LifeSciences #DigitalHealth #AI #pharmaceutical #biotechnology #medicaldevice…
 
Summary Dr. Andy Vick shares some of the things that surprised him throughout his career and he discusses his passion for reptiles and his experience discussing the pharmaceutical potential of venom with future toxicologists at Ashland University. Next, Andrew Vick discusses his role as an adjunct professor at Ohio State University, his involvement in academia, and how he got into it. We discuss a story about a clinical study that restored hearing in children with gene therapy. The conversation concludes with a discussion about the impact of professional organizations like AAPS on the industry and the importance of networking and fellowship. Takeaways Cancer doesn’t have the same death sentence - fear factor it used to have 30+ years ago. It takes about 10 years for a newly discovered compound to make it on the market. Andrew Vick is passionate about reptiles and has a collection of rare reptiles. He enjoys educating others about reptiles and their pharmaceutical potential, particularly venom. There’s a shift from small molecules to biologics in the past 5 years. Andrew Vick visited Ashland University to discuss the pharmaceutical potential of venom with future toxicologists, combining his passion for reptiles and pharmaceutical science. Andrew Vick is an adjunct professor at Ohio State University, where he teaches in the College of Pharmacy Division of Pharmaceutical Chemistry. His role as an adjunct professor involves giving guest lectures, providing career and professional development for students, and serving on the Dean's Corporate Council. Andrew Vick is also involved in evaluating assets developed in academia and collaborating with industry to develop strategies for bringing products to the clinic. We discuss a study by Regeneron that used gene therapy to restore hearing in children with mutations in the otoferlin gene. Regarding Cell-Gene Therapy we have a lot to learn both from the positive pharmacological potential, but also from a safety and tolerability standpoint. Professional organizations like AAPS play a crucial role in networking and fellowship, providing opportunities for collaboration and learning in the pharmaceutical industry. Sound Bites "I have just a passion for reptiles and have accumulated a small and pretty rare collection of reptiles from around the world." “It's probably a good 10 years from the glimmer in a biochemist's eyes to on the market.” “There’s a logarithmic difference between great and good.” “Just use your imagination on a way to tackle a disease and then find a way.” “Cell and gene therapy opens the door to a whole different category of opportunities.” “AAPS is just kind of part of my DNA.” Chapters 00:21 - Surprises in Dr. Vick’s Career 02:24 - The Cyclical Nature of Technology 03:30 - Exploring the Pharmaceutical Potential of Venom 05:35 - Improvements in Cancer and Other Diseases In The Past 30 Years 10:13 - Educating Future Toxicologists about Reptiles and Pharmaceuticals 15:45 - Andrew Vick's Role as an Adjunct Professor at Ohio State University 21:21 - New News!! - Restoring Hearing in Children with Gene Therapy 27:27 - The Impact of Professional Organizations on the Industry, AAPS New News Story: The 'little protein factory' that could: Regeneron gene therapy restores hearing in 2 children https://www.fiercebiotech.com/biotech/little-protein-factory-could-regeneron-gene-therapy-restores-hearing-2-kids How to reach us: Dr. Andy Vick https://www.linkedin.com/in/andy-vick-4467189/ Attralus: https://www.attralus.com/ Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Image credits: Pharmacognosy - https://pharmacognosy-phytochemistry-natural-products.pharmaceuticalconferences.com/events-list/industrial-pharmacognosy #biotechnology #science #research #toxicology #reptiles #academia #cellgenetherapy #AAPS…
 
Summary Dr. Andy Vick discusses his work at Attralus Therapeutics, a biotech company focused on developing treatments for systemic amyloidosis. He explains the etiology of the disease and how Attralus is attacking it using therapeutic antibodies with a pan amyloid reactive peptide sequence. The company is also developing a diagnostic tool to visualize amyloid burden in patients. Dr. Vick emphasizes the importance of toxicology in drug discovery and development, describing its role in evaluating the adverse side effects of drugs and ensuring safety. He also highlights the challenges of finding animal models for rare diseases like amyloidosis. In this part of the conversation, Andrew Vick discusses his transition from working in a contract research organization (CRO) to a small biotech company. He highlights the similarities and differences between working in biotech, pharma, and CROs, emphasizing the motivation to help others and improve the quality of life. The conversation then shifts to a discussion about a novel mRNA-based cancer vaccine for glioblastoma, which shows promise in early research. The vaccine wraps the RNA specific to a patient's tumor in lipid nanoparticles, stimulating a robust immune response against the cancer. Takeaways Attralus Therapeutics is focused on developing treatments for systemic amyloidosis using therapeutic antibodies with a panamyloid reactive peptide sequence. The company is also developing a diagnostic tool to visualize amyloid burden in patients. Toxicology plays a crucial role in drug discovery and development, evaluating the adverse side effects of drugs and ensuring safety. Finding animal models for rare diseases like amyloidosis can be challenging. Andrew Vick transitioned from working in a contract research organization (CRO) to a small biotech company, highlighting the similarities and differences between the two. The motivation to help others and improve the quality of life is a common thread in biotech, pharma, and CROs. A novel mRNA-based cancer vaccine for glioblastoma shows promise in early research, stimulating a robust immune response against the cancer. Sound Bites "Attralus Therapeutics is focusing on biologic-based therapeutics and diagnostics related to amyloidosis." "Toxicology is the science of evaluating the adverse side effects of drugs." "Attralus Therapeutics' lead product is a therapeutic antibody with a panamyloid reactive peptide sequence." "This novel mRNA vaccine shows promise against deadly brain cancer." Chapters 02:22 Dr. Vick’s Charity Work in Brazil 06:30 Introduction to Attralus Therapeutics 07:41 Developing Treatments for Systemic Amyloidosis 10:35 The Role of Toxicology in Drug Discovery and Development 16:38 Using Animal Models Studying Amyloidosis 22:06 The History of Attralus and Dr. Vick’s Transition There from CRO 32:45 New News! - Promising Results of an mRNA-Based Brain Cancer Vaccine New News Story: Glioblastoma vaccine turns brain tumors from cold to hot in humans and dogs https://www.fiercebiotech.com/research/glioblastoma-vaccine-turns-brain-tumors-cold-hot-humans-and-dogs Media credits: Pilot https://www.amazon.com/Military-Aircraft-Cockpit-Photograph-Picture/dp/B07Z2KM6KY UF https://www.clickorlando.com/news/florida/2024/03/11/university-of-florida-axes-diversity-and-inclusion-office-under-gop-led-law-aimed-at-ridding-similar-programs/ Music Track: "CLARITY", Mifune Music provided by https://slip.stream Download / Stream: https://get.slip.stream/KFCilm Keywords Attralus Therapeutics, systemic amyloidosis, therapeutic antibodies, panamyloid reactive peptide sequence, diagnostic tool, toxicology, drug discovery, drug development, animal models, rare diseases, transition, contract research organization, CRO, biotech, pharma, motivation, quality of life, mRNA-based cancer vaccine, glioblastoma, lipid nanoparticles, immune response #biotechnology #science #research #toxicology #glioblastoma #braincancer #vaccine #amyloidosis…
 
A Diagnostic Breakthrough for Alzheimer’s Summary In this conversation, Dr. Jonathan Hill discusses his work in nanopore sequencing-based technology and its applications in genetic and epigenetic research. He shares his experiences working in Brazil and his passion for preserving the rainforest. The conversation also explores the use of AI in analyzing the genetic underpinnings of tobacco addiction and the potential impact on addiction treatment. Dr. Hill highlights his lab's breakthrough in identifying early biomarkers for Alzheimer's disease using DNA methylation signatures. Takeaways Nanopore sequencing is a powerful technology that allows for real-time analysis of native DNA and RNA, regardless of length, and provides valuable insights into genetic and epigenetic research. Preserving the rainforest is crucial, and initiatives like the Rainforest Trust play a vital role in protecting the biodiversity and resources found in these ecosystems. AI technologies, when used in conjunction with genetic research, can accelerate the identification of candidate genes associated with complex conditions like tobacco addiction, leading to personalized approaches for smoking cessation and addiction treatment. The integration of AI technologies in genetic research should be approached with caution, as the black box nature of AI can limit our understanding of the underlying biology. It is important to carefully test and explain AI models to build trust among users. The use of nanopore sequencing and DNA methylation signatures shows promise in the early detection of Alzheimer's disease, potentially allowing for personalized approaches to treatment and intervention. Sound Bites "One of my bucket list items, one of my dreams would be to set up a nanopore sequencing lab in the Amazon and just sequence that biodiversity and create that data so we could glean it for everything it's worth and learn so much about how our world works." "Nanopore sequencing is based on protein nanopores that exist in nature, and these particular nanopores can pass DNA through the pore." "AI technologies, when used in conjunction with genetic research, can accelerate the identification of candidate genes associated with complex conditions like tobacco addiction, leading to personalized approaches for smoking cessation and addiction treatment." “Biology is not rocket science, it’s much harder.” "Better diagnosis comes better treatment." Chapters 00:00 Introduction 02:51 Donation to the Rainforest Trust & Time in Brazil 06:37 How Nanopore Sequencing Works 12:45 New News! AI and the Genetic Code of Tobacco Addiction 15:20 Using AI in Nanopore Sequencing at Wasatch Labs and Diagnostics 21:14 Finding Cell-Free DNA for Fertility Treatments 22:56 Breakthrough - Finding Early Biomarkers for Alzheimer’s New News Article Breaking the Genetic Code of Tobacco Addiction https://neurosciencenews.com/genetics-tobacco-addiction-ai-25937/ How to reach us: Dr. Jonathan Hill https://www.linkedin.com/in/jonathon-t-hill/ Wasatch Labs: https://www.wasatchbiolabs.com/ Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ ECI - https://eci-rx.com / Image Credits Rainforest Trust - https://www.rainforesttrust.org/ https://www.envirobuild.com/blog/rainforest-trust Fire Sponge https://stock.adobe.com/ Amazon Photos: Shutterstock Medicine Man https://www.rollingstone.com/music/music-lists/stills-from-the-movie-medicine-man-32217/medicine-man-5-159239/ https://www.solarnavigator.net/films_movies_actors/medicine_man.htm Oxford Nanopore Technologies How nanopore sequencing works https://www.youtube.com/watch?v=RcP85JHLmnI Keywords nanopore sequencing, genetic research, epigenetics, rainforest preservation, AI, tobacco addiction, addiction treatment, Alzheimer's disease, DNA methylation #nanopore, #geneticresearch, #epigenetics, #AI, #addiction, #alzheimers, #DNA…
 
Loading …

प्लेयर एफएम में आपका स्वागत है!

प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।

 

icon Daily Deals
icon Daily Deals
icon Daily Deals

त्वरित संदर्भ मार्गदर्शिका

अन्वेषण करते समय इस शो को सुनें
प्ले